Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
45,497
archived clinical trials in
Breast Cancer

Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Butler Memorial Hospital
mi
from
Butler, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Butler Memorial Hospital
mi
from
Butler, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center
mi
from
Danville, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Fitzgerald Hospital
mi
from
Darby, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Doylestown Hospital
mi
from
Doylestown, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Doylestown Hospital
mi
from
Doylestown, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Delaware County Memorial Hospital
mi
from
Drexel Hill, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Einstein Medical Center Montgomery
mi
from
East Norriton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Einstein Medical Center Montgomery
mi
from
East Norriton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Pocono Medical Center
mi
from
East Stroudsburg, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Pocono Medical Center
mi
from
East Stroudsburg, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Easton Hospital
mi
from
Easton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Easton Hospital
mi
from
Easton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ephrata Cancer Center
mi
from
Ephrata, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ephrata Cancer Center
mi
from
Ephrata, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Ephrata Community Hospital
mi
from
Ephrata, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Ephrata Community Hospital
mi
from
Ephrata, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Adams Cancer Center
mi
from
Gettysburg, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Adams Cancer Center
mi
from
Gettysburg, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Centers - Arnold Palmer Pavilion
mi
from
Greensburg, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Centers - Arnold Palmer Pavilion
mi
from
Greensburg, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cherry Tree Cancer Center
mi
from
Hanover, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cherry Tree Cancer Center
mi
from
Hanover, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
mi
from
Hazleton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Center-Cancer Center Hazleton
mi
from
Hazleton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC-Johnstown/John P. Murtha Regional Cancer Center
mi
from
Johnstown, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC-Johnstown/John P. Murtha Regional Cancer Center
mi
from
Johnstown, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Saint Mary Medical and Regional Cancer Center
mi
from
Langhorne, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Saint Mary Medical and Regional Cancer Center
mi
from
Langhorne, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lewistown Hospital
mi
from
Lewistown, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lewistown Hospital
mi
from
Lewistown, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center at UPMC McKeesport
mi
from
McKeesport, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center at UPMC McKeesport
mi
from
McKeesport, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Holy Redeemer Hospital and Medical Center
mi
from
Meadowbrook, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Holy Redeemer Hospital and Medical Center
mi
from
Meadowbrook, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Paoli Memorial Hospital
mi
from
Paoli, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Paoli Memorial Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital of Philadelphia
mi
from
Philadelphia, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital of Philadelphia
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
mi
from
Philadelphia, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC-Passavant Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC-Saint Clair Hospital Cancer Center
mi
from
Pittsburgh, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC-Saint Clair Hospital Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC-Saint Margaret
mi
from
Pittsburgh, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC-Saint Margaret
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC Shadyside Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
West Penn Hospital
mi
from
Pittsburgh, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
West Penn Hospital
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Guthrie Medical Group PC-Robert Packer Hospital
mi
from
Sayre, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Guthrie Medical Group PC-Robert Packer Hospital
mi
from
Sayre, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Hematology and Oncology Associates of North East Pennsylvania
mi
from
Scranton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Hematology and Oncology Associates of North East Pennsylvania
mi
from
Scranton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital
mi
from
Scranton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital
mi
from
Scranton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Scranton Hematology Oncology
mi
from
Scranton, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Scranton Hematology Oncology
mi
from
Scranton, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Grand View Hospital
mi
from
Sellersville, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Grand View Hospital
mi
from
Sellersville, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
UPMC Cancer Center at UPMC Northwest
mi
from
Seneca, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Geisinger Medical Group
mi
from
State College, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Geisinger Medical Group
mi
from
State College, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Mount Nittany Medical Center
mi
from
State College, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Mount Nittany Medical Center
mi
from
State College, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Associates In Hematology Oncology PC-Upland
mi
from
Upland, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Associates In Hematology Oncology PC-Upland
mi
from
Upland, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Chester County Hospital
mi
from
West Chester, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Chester County Hospital
mi
from
West Chester, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Reading Hospital
mi
from
West Reading, PA
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Reading Hospital
mi
from
West Reading, PA
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Miriam Hospital
mi
from
Providence, RI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Miriam Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
AnMedical Health Cancer Center
mi
from
Anderson, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Beaufort Memorial Hospital
mi
from
Beaufort, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Beaufort Memorial Hospital
mi
from
Beaufort, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Charleston Hematology Oncology Associates-Roper
mi
from
Charleston, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Charleston Hematology Oncology Associates-Roper
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lowcountry Hematology Oncology PA-West Ashley
mi
from
Charleston, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lowcountry Hematology Oncology PA-West Ashley
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Medical University of South Carolina
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Roper Hospital
mi
from
Charleston, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Roper Hospital
mi
from
Charleston, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Greenville Health System Cancer Institute-Butternut
mi
from
Greenville, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute-Butternut
mi
from
Greenville, SC
Click here to add this to my saved trials
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer
A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Greenville Health System Cancer Institute/Eastside
mi
from
Greenville, SC
Click here to add this to my saved trials